VA Launches Major Psilocybin Trial for Veteran PTSD and Depression
The Department of Veterans Affairs is launching the PIVOT clinical trial to evaluate psilocybin's safety and effectiveness for treating treatment-resistant major depressive disorder and PTSD in at least 240 veterans across five VA medical centers. The double-blind, randomized study runs through June 2031, offering one or two doses with therapeutic support. It follows a small Ohio State study where 75% of veterans no longer met PTSD criteria after treatment. The initiative is backed by a Trump executive order accelerating FDA review of psychedelic therapies.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection
Cross-source coverage
Wire timeline
Major VA study to examine effectiveness of psilocybin on depression, PTSD
The Department of Veterans Affairs is launching a major clinical trial called PIVOT to evaluate the safety and effectiveness of psilocybin, the psychoactive ingredient in magic mushrooms, for treating treatment-resistant major depressive disorder and PTSD in veterans. The study will involve at least 240 veterans across five VA medical centers and run through June 2031. Participants will receive one or two doses of psilocybin or a placebo with therapeutic support, with follow-up evaluations. The initiative follows a Trump executive order in April 2026 directing accelerated review of psychedelic therapies. A smaller Ohio State University study published in July 2026 found that 75% of veteran participants no longer met PTSD criteria after psilocybin treatment with no serious adverse effects. The VA is also involved in 20 other clinical trials on psychedelics including MDMA and LSD.
Major VA study to examine effectiveness of psilocybin on depression, PTSD
The Department of Veterans Affairs is launching the PIVOT study, a major clinical trial to evaluate the safety and effectiveness of psilocybin (the psychoactive ingredient in 'magic mushrooms') for treating treatment-resistant major depressive disorder and PTSD in veterans. The double-blind, randomized trial will involve at least 240 veterans across five VA medical centers, with participants receiving one or two doses of psilocybin or a placebo along with therapeutic support, and follow-up through June 2031. The study follows a small Ohio State University trial where 75% of veterans with severe PTSD no longer met clinical criteria after psilocybin treatment. The initiative is supported by a Trump executive order directing accelerated FDA review of psychedelic therapies and a recent VA-HHS agreement to increase coordination on psychedelic research. The VA is currently involved in 20 clinical trials on psychedelic treatments, including MDMA and LSD.
Major VA study to examine effectiveness of psilocybin on depression, PTSD
The Department of Veterans Affairs is launching the PIVOT trial, a major study on the safety and effectiveness of psilocybin (the psychoactive ingredient in 'magic mushrooms') for treating treatment-resistant major depressive disorder and PTSD in veterans. The double-blind, randomized trial will include at least 240 veterans at five VA medical centers through June 2031. Participants will receive one or two doses of psilocybin or a placebo with therapeutic support, with follow-up evaluations. The study follows a small Ohio State University trial where 75% of veteran participants no longer met PTSD criteria after psilocybin treatment. The research is part of a broader push under a Trump executive order to accelerate psychedelic therapy research, with VA involved in 20 current clinical trials on psychedelics including MDMA and LSD.
Show 12 older updatesHide older updates
Major VA study to examine effectiveness of psilocybin on depression, PTSD
The Department of Veterans Affairs is launching the PIVOT trial to study the safety and effectiveness of psilocybin, the psychoactive ingredient in magic mushrooms, for treating veterans with treatment-resistant major depressive disorder and PTSD. The double-blind, randomized study will include at least 240 veterans across five VA medical centers and run through June 2031. Participants will receive one or two doses of psilocybin or a placebo with therapeutic support. The initiative follows a Trump executive order in April 2026 directing accelerated review of psychedelic therapies. A prior small study by Ohio State University found that 75% of veteran participants no longer met PTSD criteria after psilocybin treatment. The VA is also involved in 20 other clinical trials on psychedelics including MDMA and LSD.
Major VA study to examine effectiveness of psilocybin on depression, PTSD
The Department of Veterans Affairs is launching the PIVOT trial to evaluate the safety and effectiveness of psilocybin, the psychoactive ingredient in 'magic mushrooms,' for treating treatment-resistant major depressive disorder and PTSD in veterans. The double-blind, randomized study will include at least 240 veterans across five VA medical centers, with treatment involving one or two doses of psilocybin or placebo alongside therapeutic support, and follow-up through June 2031. This follows a small Ohio State University study where 75% of veteran participants no longer met PTSD criteria after psilocybin therapy. The research is part of a broader push under a Trump executive order directing accelerated FDA review of psychedelic therapies, and the VA is currently involved in 20 clinical trials on psychedelic treatments including MDMA and LSD.
Major VA study to examine effectiveness of psilocybin on depression, PTSD
The Department of Veterans Affairs is launching the PIVOT study to evaluate the safety and effectiveness of psilocybin, the psychoactive ingredient in magic mushrooms, for treating treatment-resistant major depressive disorder and PTSD in veterans. The double-blind, randomized trial will include at least 240 veterans across five VA medical centers, with participants receiving one or two doses of psilocybin or a placebo along with therapeutic support, and will run through June 2031. This follows a small Ohio State University study where 75% of veteran participants no longer met PTSD criteria after psilocybin treatment. The initiative is backed by a Trump executive order directing accelerated review of psychedelic therapies, and the VA is currently involved in 20 clinical trials on psychedelic treatments including MDMA and LSD.
Major VA study to examine effectiveness of psilocybin on depression, PTSD
The Department of Veterans Affairs is launching the PIVOT clinical trial to evaluate the safety and effectiveness of psilocybin, the psychoactive ingredient in magic mushrooms, for treating treatment-resistant major depressive disorder and PTSD in veterans. The study will involve at least 240 veterans at five VA medical centers through June 2031, using a double-blind, randomized design with two doses of psilocybin or placebo plus therapeutic support. This follows a small Ohio State University study where 75% of veteran participants no longer met PTSD criteria after psilocybin therapy. The initiative is backed by a Trump executive order directing the FDA to accelerate psychedelic therapy reviews, and a recent VA-HHS agreement to increase coordination on psychedelic research. The VA is currently involved in 20 clinical trials on psychedelic treatments, including MDMA and LSD.
Major VA study to examine effectiveness of psilocybin on depression, PTSD
The Department of Veterans Affairs is launching the PIVOT trial, a major study on the safety and effectiveness of psilocybin (the psychoactive ingredient in 'magic mushrooms') for treating treatment-resistant major depressive disorder and PTSD in veterans. The double-blind, randomized trial will include at least 240 veterans across five VA medical centers, with participants receiving one or two doses of psilocybin or a placebo along with therapeutic support, and follow-up evaluations through June 2031. The study follows a small Ohio State University trial where 75% of veteran participants no longer met PTSD criteria after psilocybin treatment. The initiative is backed by a Trump executive order directing accelerated FDA review of psychedelic therapies, and an HHS-VA agreement to increase coordination on psychedelic research. The VA is currently involved in 20 clinical trials on psychedelic treatments, including MDMA and LSD.
Major VA study to examine effectiveness of psilocybin on depression, PTSD
The Department of Veterans Affairs is launching a major clinical trial called PIVOT (Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression) to evaluate the safety and effectiveness of psilocybin, the psychoactive ingredient in magic mushrooms, for treating major depressive disorder and PTSD in veterans. The study will involve at least 240 veterans with difficult-to-treat depression, some of whom also have PTSD, across five VA medical centers through June 2031. Participants will receive one or two doses of psilocybin or a placebo in a double-blind, randomized trial, along with therapeutic support. The initiative follows a Trump executive order in April 2026 directing accelerated review of psychedelic therapies, and a subsequent HHS-VA agreement to increase coordination on psychedelic research. A prior small study by Ohio State University found that 75% of veteran participants no longer met PTSD criteria after psilocybin treatment with no serious adverse effects. The VA is currently involved in 20 clinical trials on psychedelic treatments including MDMA and LSD.
VA launches major study on psilocybin for veteran depression and PTSD
The Department of Veterans Affairs is launching the PIVOT study, a major clinical trial to evaluate the safety and effectiveness of psilocybin (the psychoactive ingredient in 'magic mushrooms') for treating treatment-resistant major depressive disorder and PTSD in veterans. The double-blind, randomized trial will include at least 240 veterans at five VA medical centers across the U.S., with participants receiving one or two doses of psilocybin or a placebo along with therapeutic support, and follow-up assessments through June 2031. The study follows a small Ohio State University trial where 75% of veteran participants no longer met PTSD criteria after psilocybin treatment. The initiative is supported by a Trump executive order directing accelerated FDA review of psychedelic therapies, and an HHS-VA agreement to increase coordination on psychedelic research. The VA is currently involved in 20 clinical trials on psychedelic treatments including MDMA and LSD.
Major VA study to examine effectiveness of psilocybin on depression, PTSD
The Department of Veterans Affairs is launching the PIVOT trial, a major study on the safety and effectiveness of psilocybin (the psychoactive ingredient in 'magic mushrooms') for treating treatment-resistant major depressive disorder and PTSD in veterans. The double-blind, randomized trial will include at least 240 veterans across five VA medical centers, running through June 2031. Participants will receive one or two doses of psilocybin or a placebo with therapeutic support. The study follows promising results from a smaller Ohio State University trial where 75% of veteran participants no longer met PTSD criteria after treatment. The initiative is backed by a Trump executive order directing accelerated FDA review of psychedelic therapies and a new HHS-VA agreement to increase coordination on psychedelic research. The VA is currently involved in 20 clinical trials on psychedelic treatments including MDMA and LSD.
Major VA study to examine effectiveness of psilocybin on depression, PTSD
The Department of Veterans Affairs is launching the PIVOT clinical trial to evaluate the safety and effectiveness of psilocybin, the psychoactive ingredient in magic mushrooms, for treating treatment-resistant major depressive disorder and PTSD in veterans. The study will involve at least 240 veterans at five VA medical centers through June 2031, using a double-blind, randomized design with two doses of psilocybin or placebo alongside therapeutic support. This follows a small Ohio State University study where 75% of veteran participants no longer met PTSD criteria after treatment. The initiative is backed by a Trump executive order directing accelerated FDA review of psychedelic therapies and a recent VA-HHS agreement to increase coordination on psychedelic research. The VA is also involved in 20 other clinical trials on psychedelics including MDMA and LSD.
Major VA study to examine effectiveness of psilocybin on depression, PTSD
The Department of Veterans Affairs is launching a major clinical trial called PIVOT to evaluate the safety and effectiveness of psilocybin, the psychoactive ingredient in magic mushrooms, for treating treatment-resistant major depressive disorder and PTSD in veterans. The study will involve at least 240 veterans at five VA medical centers across the U.S., running through June 2031. Participants will receive one or two doses of psilocybin or a placebo in a double-blind, randomized design, along with therapeutic support. The initiative follows a Trump executive order in April 2026 directing accelerated review of psychedelic therapies, and a subsequent HHS-VA agreement to boost research coordination. A prior small study by Ohio State University found that 75% of veteran participants no longer met PTSD criteria after psilocybin treatment with no serious adverse effects. The VA is currently involved in 20 clinical trials on psychedelic treatments, including MDMA and LSD.
Major VA study to examine effectiveness of psilocybin on depression, PTSD
The Department of Veterans Affairs is launching the PIVOT study, a clinical trial to evaluate the safety and effectiveness of psilocybin (the psychoactive ingredient in 'magic mushrooms') for treating treatment-resistant major depressive disorder and PTSD in at least 240 veterans. The double-blind, randomized trial will take place at five VA medical centers through June 2031, with participants receiving one or two doses of psilocybin or a placebo alongside therapeutic support. This follows a small Ohio State University study where 75% of veterans with severe PTSD no longer met clinical criteria after psilocybin treatment. The initiative is backed by a Trump executive order directing accelerated FDA review of psychedelic therapies and an HHS-VA agreement to increase coordination on psychedelic research. The VA is currently involved in 20 clinical trials on psychedelic treatments, including MDMA and LSD.
Major VA study to examine effectiveness of psilocybin on depression, PTSD
The Department of Veterans Affairs is launching the PIVOT clinical trial to evaluate the safety and effectiveness of psilocybin, the psychoactive ingredient in magic mushrooms, for treating treatment-resistant major depressive disorder and PTSD in veterans. The study will involve at least 240 veterans at five VA medical centers through June 2031, using a double-blind, randomized design with two doses of psilocybin or placebo alongside therapeutic support. This follows a small Ohio State University study where 75% of veteran participants no longer met PTSD criteria after psilocybin therapy. The initiative is backed by a Trump executive order accelerating psychedelic therapy research, and the VA is involved in 20 current clinical trials on psychedelic treatments including MDMA and LSD.